Revive Therapeutics Ltd.
RVV
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.30% | -31.15% | -41.26% | 30.42% | 39.40% |
| Depreciation & Amortization | -100.00% | -100.00% | -75.00% | -50.00% | -25.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.56% | -50.37% | -55.16% | -15.64% | -18.75% |
| Operating Income | 62.56% | 50.37% | 55.16% | 15.64% | 18.75% |
| Income Before Tax | -86.21% | -92.13% | 7.51% | -22.06% | -12.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.21% | -92.13% | 7.51% | -22.06% | -12.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.21% | -92.13% | 7.51% | -22.06% | -12.06% |
| EBIT | 62.56% | 50.37% | 55.16% | 15.64% | 18.75% |
| EBITDA | 62.56% | 50.37% | 55.16% | 15.63% | 18.75% |
| EPS Basic | -76.19% | -79.05% | 21.59% | 0.00% | 7.89% |
| Normalized Basic EPS | 60.00% | 55.00% | 54.76% | 25.53% | 32.20% |
| EPS Diluted | -76.19% | -79.05% | 21.59% | 0.00% | 7.89% |
| Normalized Diluted EPS | 60.00% | 55.00% | 54.76% | 25.53% | 32.20% |
| Average Basic Shares Outstanding | 6.73% | 10.29% | 17.55% | 20.26% | 18.67% |
| Average Diluted Shares Outstanding | 6.73% | 10.29% | 17.55% | 20.26% | 18.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |